Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia

Kasture, Vaishali; Sundrani, Deepali; Dalvi, Surabhi; Swamy, Mayur; Kale, Anvita; Joshi, Sadhana

doi:10.1007/s11010-019-03599-4

Cited by 15 publications

(10 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, a time frame modification of treatment enables the pharmacologically induced L-NAME model of pre-eclampsia to mimic both preterm (treatment from gestational day 4-8) and term (treatment from gestational day 8-14) pre-eclampsia 334 . This model has been used to determine the effects of sildenafil citrate 335,336 , sodium hydrosulfide 337 , L-arginine 338 , omega 3 fatty acids and vitamin E 339 .…”

Section: ();mentioning

confidence: 99%

Pre-eclampsia

Dimitriadis

Rolnik

Zhou

et al. 2023

Nat Rev Dis Primers

213

View full text Add to dashboard Cite

Pre-eclampsia is a life-threatening disease of pregnancy unique to humans and a leading cause of maternal and neonatal morbidity and mortality. Women who survive pre-eclampsia have reduced life expectancy, with increased risks of stroke, cardiovascular disease and diabetes, while babies from a pre-eclamptic pregnancy have increased risks of preterm birth, perinatal death and neurodevelopmental disability and cardiovascular and metabolic disease later in life. Preeclampsia is a complex multisystem disease, diagnosed by sudden-onset hypertension (>20 weeks of gestation) and at least one other associated complication, including proteinuria, maternal organ dysfunction or uteroplacental dysfunction. Pre-eclampsia is found only when a placenta is or was recently present and is classified as preterm (delivery <37 weeks of gestation), term (delivery ≥37 weeks of gestation) and postpartum pre-eclampsia. The maternal syndrome of pre-eclampsia is driven by a dysfunctional placenta, which releases factors into maternal blood causing systemic inflammation and widespread maternal endothelial dysfunction. Available treatments target maternal hypertension and seizures, but the only 'cure' for pre-eclampsia is delivery of the dysfunctional placenta and baby, often prematurely. Despite decades of research, the aetiology of pre-eclampsia, particularly of term and postpartum pre-eclampsia, remains poorly defined. Significant advances have been made in the prediction and prevention of preterm pre-eclampsia, which is predicted in early pregnancy through combined screening and is prevented with daily low-dose aspirin, starting before 16 weeks of gestation. By contrast, the prediction of term and postpartum pre-eclampsia is limited and there are no preventive treatments. Future research must investigate the pathogenesis of pre-eclampsia, in particular of term and postpartum pre-eclampsia, and evaluate new Nature Reviews Disease Primers | (2023) 9:8 2 0123456789();: Primer Epidemiology Incidence and mortalityThe global prevalence of all pre-eclampsia in the years 2002-2010 was estimated at 4.6% of deliveries but reported regional rates varied between 1% and 5.6% 14 . Where reported, the prevalence of preterm pre-eclampsia is <1% [15][16][17][18] . The prevalence of pre-eclampsia is generally reported as lower in low-income and middle-income countries (LMICs) (except sub-Saharan Africa) than in high-income countries (HICs) 19,20 ; however, it is likely that differences in classification, access to prenatal care and under-reporting in LMICs affect prevalence data 20,21 . Furthermore, most pre-eclampsia research is performed in HICs, potentially leading to bias and generalizability concerns in the populations sampled and the research questions asked.Hypertensive disorders of pregnancy (including pre-eclampsia) are the second most common cause (behind haemorrhage) of maternal Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rights...

show abstract

Section: ();mentioning

confidence: 99%

Pre-eclampsia

Dimitriadis

Rolnik

Zhou

et al. 2023

Nat Rev Dis Primers

213

View full text Add to dashboard Cite

show abstract

“…This clearly demonstrates that administration of L-NAME caused an up-regulation of this key pathway, offering a compelling model of preeclampsia. In other studies, L-NAME rodent models demonstrate mixed results for changes in Flt1 and its soluble circulating form, although some of these discrepancies may be due to the varied L-NAME concentrations and routes of administration used (31,51,52,53,54,55,56,57,58,59,60,61,62). Complex viral vector S13.…”

Section: Discussionmentioning

confidence: 98%

The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health

et al. 2022

View full text Add to dashboard Cite

Preeclampsia affects ∼2–8% of pregnancies worldwide. It is associated with increased long-term maternal cardiovascular disease risk. This study assesses the effect of the vasoconstrictor N(ω)-nitro-L-arginine methyl ester (L-NAME) in modelling preeclampsia in mice, and its long-term effects on maternal cardiovascular health. In this study, we found that L-NAME administration mimicked key characteristics of preeclampsia, including elevated blood pressure, impaired fetal and placental growth, and increased circulating endothelin-1 (vasoconstrictor), soluble fms-like tyrosine kinase-1 (anti-angiogenic factor), and C-reactive protein (inflammatory marker). Post-delivery, mice that received L-NAME in pregnancy recovered, with no discernible changes in measured cardiovascular indices at 1-, 2-, and 4-wk post-delivery, compared with matched controls. At 10-wk post-delivery, arteries collected from the L-NAME mice constricted significantly more to phenylephrine than controls. In addition, these mice had increased kidney Mmp9:Timp1 and heart Tnf mRNA expression, indicating increased inflammation. These findings suggest that though administration of L-NAME in mice certainly models key characteristics of preeclampsia during pregnancy, it does not appear to model the adverse increase in cardiovascular disease risk seen in individuals after preeclampsia.

show abstract

“…Omega-3 fatty acids have also been proven to improve the levels of vascular endothelial growth factor (VEGF) and transcription factors like PPAR-g, reducing the severity of late-onset preeclampsia rather early-onset preeclampsia [ 35 ]. In view of the lower VEGFR-1 protein levels in the early-onset preeclampsia group as compared to the control and the higher severity of angiogenic/anti-angiogenic imbalance [ 36 ], it is not surprising that maternal supplementation of omega-3 fatty acids fails to work for women with early-onset preeclampsia. Sphingolipids constitute an important class of bioactive lipids, including ceramide and sphingosine-1-phosphate (S1P).…”

Section: Roles Of Lipids In Preeclampsia Pathogenesismentioning

confidence: 99%

Dissecting the Roles of Lipids in Preeclampsia

Yang

Wang

et al. 2022

Metabolites

View full text Add to dashboard Cite

Preeclampsia is a multisystem pregnancy disorder that is characterized by different degrees of placental malperfusion, with release of antiangiogenic factors into the circulation, leading to maternal vascular endothelial injury and high blood pressure. As a major cause of maternal and perinatal mortality and morbidity worldwide, once preeclampsia has been diagnosed, there are no curative treatments except for delivery. Lipids serve as ubiquitous and multifunctional metabolites that are integral and essential to many diverse functions on both a cellular and organismal level. Lipid metabolic abnormalities have emerged as potential risk factors for the development and progression of preeclampsia. This review comprehensively examines decades of discovery to illuminate the roles of lipids and dysregulation in the levels of various lipid classes in preeclampsia. In addition, the roles of lipids are summarized to further understand the pathogenic mechanisms of preeclampsia. Overall, the review highlights the promising potential of pathophysiology and lipid-targeting therapeutic strategies in preeclampsia.

show abstract

Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia

Cited by 15 publications

References 53 publications

Pre-eclampsia

Pre-eclampsia

The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health

Dissecting the Roles of Lipids in Preeclampsia

Contact Info

Product

Resources

About